The global CircRNA synthesis market size was evaluated at USD 186 million in 2024 and is expected to grow around USD 813.48 million by 2034, registering a CAGR of 15.9% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 215.57 Million |
| Market Size by 2034 | USD 813.48 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 15.9% |
The circRNA synthesis market refers to the production, distribution, and use of the circRNA, which is synthesized by the synthesis of one or many precursor linear RNA, followed by RNA circularization mediated by chemical or enzymatical ligation. The precursor linear RNAs used for circRNA synthesis can be synthesized by chemical and enzymatic approaches. CircRNA synthesis exhibits lower immunogenicity and lower cytotoxicity in the absence of modification. In addition to miRNAs, circRNAs can act as protein decoys to influence cellular functions. With the unique benefits of effective synthesis and stable high expression, circRNA has already demonstrated potential in vaccines, immunotherapy, and protein replacement therapies, promising innovative and effective treatment options for human diseases.
CircRNA has its own unique benefits in the development of vaccines and nucleic acid drugs. Firstly, it is less susceptible to degradation and it is more stable than mRNA vaccines and nucleic acid drugs. Secondly, rolling loop translation requires lower amounts than mRNA and is, therefore, less toxic. CircRNA plays important functions in many cellular processes, including controlling gene expression through forming complexes by binding to RNA-linked proteins and constituting miRNA sponges.
Technological advancements help to drive the growth of the circRNA synthesis market. Technological advancements, mainly in machine learning (ML) and artificial intelligence (AI), are enhancing RNA sequence design and synthesis efficiency. CircRNAs are highly stable and resistant to degradation due to their covalently closed-loop structure. This stability ensures prolonged expression of engineered constructs in therapeutic applications, such as CAR T cells. With advancements in technologies, the widespread use of circRNA vaccines for preventing infectious diseases and treating tumor malignancies holds promise for the future. Circular RNA is an emerging technology that experts believe holds a lot of promise for next-generation vaccines and gene therapies.
Patients generate huge amounts of data - patient records from X-rays to blood test results. Replacing paper with computerized summaries makes patient care easier and more efficient. The benefits of advanced technologies include mHealth, lower healthcare costs, enhanced medication safety, enhanced communication, empowered patients, better diagnostics, augmented reality, 3D printing, improved public health, improved diagnostic accuracy, robotics, remote monitoring devices, patient outcomes, wearables, electronic health records, and telemedicine.
Growing investment in RNA-based research and development is driving the growth of the circRNA synthesis market. Increasing investment in RNA therapeutics has tremendous potential to deliver new options for currently untreatable diseases, especially in infectious diseases, cancer, liver, and metabolic diseases, and rare diseases. The advantages of RNA therapy include no risk of genotoxicity, useful for rare diseases, long-term effects, fast production, and targeting undruggable targets.
Additionally, it can regulate gene expression, which means it can turn genes on or off in response to environmental changes. In other words, studying RNA is essential to understanding how DNA information is transformed into functional products like proteins, which allow cells to respond to their environment. RNA can be manipulated with the simplicity characteristic of DNA to produce nanoparticles with a diversity of quaternary structures by self-assembly. In addition, RNA is tremendously versatile in its function and some RNA molecules display catalytic activities much like proteins.
The expansion of regenerative therapies and precision medicine is raising the demand for high-quality circRNA, driving the growth of the circRNA synthesis market. Unlike traditional reactive medicine, which only repairs damage, regenerative medicine enhances the health of the tissues and bones it treats. By nourishing your skin, bones, tendons, and muscles with super concentrated platelets and fresh new cells, regenerative medicine helps the body parts grow stronger. Personalized medicines are many, ranging from improving diagnostics accuracy to identifying the best treatment option for a patient based on their characteristics, to targeted therapy that increases the likelihood of successful treatments reduces side effects, allows for better disease prevention, and most importantly reduces healthcare costs, increases patient engagement, and also promotes research and innovation.
Published by Ajit Bansod
